Expanded designs that enable clinicians to leverage data in making healthcare decisions, but privacy challenges remain.
Personalized medicine is the future of healthcare, and artificial intelligence will play a big role.
Treatment can no longer be one dimensional.
Medical device companies will be driven to evolve their business models to a more patient/consumer-centric approach.
The transition to digital in healthcare is happening at a fast pace.
Artificial intelligence and machine learning technologies have significant potential, but regulatory hurdles may stand in their way.
The revolution in data and technology should be pushing companies to focus on safeguarding intellectual property.
Topics from regenerative medicine to artificial intelligence to cannabis will be discussed.
After a series of delays and false starts, EMA is now progressing its ISO IDMP agenda with firm intent. The first implementation guide is out now for consultation, to be followed by a second actionable version by next year. Life sciences companies targeting Europe will have a year to comply with all the measures—but this will be a lot of work.
A recent report from Frost & Sullivan anticipates strong market growth but also points to opportunity for more vulnerabilities.